Last reviewed · How we verify
Flublok Quadrivalent influenza vaccine RIV4
Flublok Quadrivalent influenza vaccine RIV4 is a Biologic drug developed by Sanofi Pasteur, a Sanofi Company. It is currently in Phase 2 development. Also known as: RIV4.
At a glance
| Generic name | Flublok Quadrivalent influenza vaccine RIV4 |
|---|---|
| Also known as | RIV4 |
| Sponsor | Sanofi Pasteur, a Sanofi Company |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Randomized Influenza Vaccine Evaluation of Immune Response (PHASE4)
- Substudy 01 - Safety and Immunogenicity of One Monovalent Modified mRNA Vaccine Encoding Influenza Hemagglutinin With LNP, in Adult Participants Aged 18 to 49 Years and 60 Years and Above (PHASE1)
- Study With Quadrivalent Recombinant Influenza Vaccine (RIV4) in Participants 9 Through 49 Years of Age. (PHASE3)
- Study With Quadrivalent Recombinant Influenza Vaccine (RIV4) Compared With Egg-Based Quadrivalent Influenza Vaccine (IIV4) in Participants Aged 3 to 8 Years (PHASE3)
- A Study to Investigate the Safety and Immunogenicity of the Quadrivalent Influenza mRNA Vaccines in Adults Aged 18 Years and Above (PHASE1, PHASE2)
- Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5413 in Adult Participants18 Years of Age and Older (PHASE1, PHASE2)
- Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5410 in Adult Participants 18 Years of Age and Older (PHASE1, PHASE2)
- Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5407 in Adult Participants18 Years of Age and Older (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Flublok Quadrivalent influenza vaccine RIV4 CI brief — competitive landscape report
- Flublok Quadrivalent influenza vaccine RIV4 updates RSS · CI watch RSS
- Sanofi Pasteur, a Sanofi Company portfolio CI
Frequently asked questions about Flublok Quadrivalent influenza vaccine RIV4
What is Flublok Quadrivalent influenza vaccine RIV4?
Flublok Quadrivalent influenza vaccine RIV4 is a Biologic drug developed by Sanofi Pasteur, a Sanofi Company.
Who makes Flublok Quadrivalent influenza vaccine RIV4?
Flublok Quadrivalent influenza vaccine RIV4 is developed by Sanofi Pasteur, a Sanofi Company (see full Sanofi Pasteur, a Sanofi Company pipeline at /company/sanofi).
Is Flublok Quadrivalent influenza vaccine RIV4 also known as anything else?
Flublok Quadrivalent influenza vaccine RIV4 is also known as RIV4.
What development phase is Flublok Quadrivalent influenza vaccine RIV4 in?
Flublok Quadrivalent influenza vaccine RIV4 is in Phase 2.
Related
- Manufacturer: Sanofi Pasteur, a Sanofi Company — full pipeline
- Also known as: RIV4